“According to the WHO, pan-genotypic treatments that cure hepatitis C in 3-4 months are now available at affordable prices to millions of people in low and middle-income countries, just 5 years after their initial approval.[1] This is thanks in part to the partnership of innovators, the MPP, and manufacturers of generic medicines.

The battle against hepatitis C is far from over – treatment is reaching less than 10% of those in need, compared to the target of 80% by 2030 – but we now have the tools needed to reach people in need”.